St6gal-I Overexpression Facilitates Prostate Cancer Progression Via The Pi3k/Akt/Gsk-3 Beta/Beta-Catenin Signaling Pathway

Anwen Wei,Bo Fan,Yujie Zhao,Han Zhang,Liping Wang,Xiao Yu,Qingmin Yuan,Deyong Yang,Shujing Wang
DOI: https://doi.org/10.18632/oncotarget.11699
2016-01-01
Oncotarget
Abstract:ST6Gal-I sialyltransferase adds alpha 2,6-linked sialic acids to the terminal ends of glycan chains of glycoproteins and glycolipids. ST6Gal-I is reportedly upregulated in many cancers, including hepatocellular carcinoma, ovarian cancer and breast cancer. However, the expression and function of ST6Gal-I in prostate cancer (PCa) and the mechanism underlying this function remain largely unknown. In this study, we observed that ST6Gal-I expression was upregulated in human PCa tissues compared to non-malignant prostate tissues. High ST6Gal-I expression was positively correlated with Gleason scores, seminal vesicle involvement and poor survival in patients with PCa. ST6Gal-I knockdown in aggressive prostate cancer PC-3 and DU145 cells significantly inhibited the proliferation, growth, migration and invasion capabilities of these cells. ST6Gal-I knockdown decreased the levels of several PI3K/Akt/GSK-3 beta/beta-catenin pathway components, such as p-PI3K, (Ser473) p-Akt, (Ser9) p-GSK-3 beta and beta-catenin. Furthermore, targeting this pathway with a PI3K inhibitor or Akt RNA interference decreased p-Akt, p-GSK-3 beta and beta-catenin expression, resulting in decreased PC-3 and DU145 proliferation, migration and invasion. Taken together, these results indicate that ST6Gal-I plays a critical role in cell proliferation and invasion via the PI3K/Akt/GSK-3 beta/beta-catenin signaling pathway during PCa progression and that it might be a promising target for PCa prognosis determination and therapy.
What problem does this paper attempt to address?